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Abstract
Background: Ovarian stimulation in women with polycystic ovary syndrome (PCOS) increases the risk for perinatal 
complications. Ovulation induction by laparoscopic ovarian drilling (LOD) might improve the overall pregnancy 
outcomes. The aim of our study was to assess the adverse events or effects on pregnancy of LOD and clomiphene 
citrate (CC) stimulation in patients who received metformin.
Methods: Setting: Academic research institution. We retrospectively analyzed the courses of 40 spontaneous 
pregnancies after LOD for CC-resistance, 40 pregnancies after CC stimulation, and 40 pregnancies after metformin 
treatment alone. Patients in the LOD and the CC groups had been pre-treated with Metformin. Primary outcome 
parameters were: the rate of multiple pregnancies; the rate of early pregnancy losses/miscarriages; the development of 
gestational diabetes, pregnancy-induced hypertension, and preeclampsia/HELLP-syndrome; premature delivery; and 
birth weight.
Results: The rate of twin pregnancies did not differ between the CC group (12.5%), the LOD group (7.5%), and the 
metformin only group (2.5%, p = 0.239). Seventeen women suffered an early miscarriage. There were no differences 
with regard to the rates of gestational diabetes, pregnancy-induced hypertension, preeclampsia, and preterm delivery. 
By analyzing all pregnancy complications together, the overall pregnancy complication rate was highest in the CC 
group (70.0%, 28/40), followed by the LOD group (45.0%, 18/40), and the metformin only group (47.5%, 19/40; p = 
0.047).
Conclusions: CC, but not LOD, increases the complication rate in pregnant patients who received metformin.
Background
Despite the fact that polycystic ovary syndrome (PCOS)
remains one of the most common female endocrinopa-
thies, with an incidence of 5-10% in women of reproduc-
tive age, the etiology, pathogenesis, and even treatment of
infertile women who suffer from PCOS are still the sub-
ject of much controversy [1,2]. Clomiphene citrate (CC)
is presumed to be the first-line therapy, since it is known
to result in higher ovulation, conception, pregnancy, and
live-birth rates when compared with metformin; the
combination of both drugs did not result in a significant
benefit [3,4].
As second- and third-line therapies, gonadotropin
stimulation and laparoscopic ovarian drilling (LOD) are
recommended for CC-resistant anovulatory PCOS
patients. To date, five randomized controlled trials have
compared the effectiveness of LOD with that of gonado-
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Page 2 of 6tropin use, and all demonstrated similar pregnancy and
live birth rates for both treatment options [5-8].
Ovarian stimulation has been shown to increase the
risk for perinatal complications. Even non-in vitro fertil-
ization assisted reproductive techniques lead to a higher
risk for multiple pregnancies, prematurity, low and very
low birth weight, transfer to the neonatal intensive care
unit and various neonatal morbidity parameters [9].
Thus, it has been proposed that ovulation induction by
LOD may improve the overall outcomes of pregnancies in
PCOS patients [10]. A comparison of pregnancy out-
comes of women with PCOS who had undergone LOD
and non-PCOS pregnancy controls demonstrated a sig-
nificantly higher risk of hypertensive disorders and gesta-
tional diabetes mellitus (GDM) for the PCOS group [11].
However, whether LOD might prevent pregnancy com-
plications in women with PCOS remains hypothetical
[10].
The aim of our retrospective study was to evaluate the
pregnancy outcome after LOD compared to pregnancies
after metformin treatment and CC stimulation.
Methods
Definition
PCOS was diagnosed according to the revised European
Society of Human Reproduction and Embryology
(ESHRE) and the American Society for Reproductive
Medicine (ASRM) criteria of 2004, which were based on
the Rotterdam criteria [2]. CC resistance was defined as
the absence of developing follicles after ovarian stimula-
tion with 150 mg clomiphene citrate/day given for five
days beginning on the second day of the menstrual cycle.
Patient collective
In a retrospective cohort study, we included all CC-resis-
tant women with PCOS who underwent LOD at the
Department of Gynecology and Obstetrics of the Medical
University of Vienna, Austria, between January 2001 and
December 2008, and who became spontaneously preg-
nant within one year after the operation. Of a total of 125
patients who underwent LOD, all necessary data were
available for 75 patients (60.0%). Forty women became
spontaneously pregnant after LOD and were included in
this analysis, whereas women in need of CC stimulation
after LOD were excluded (Group 1).
Of a total of 125 PCOS women who had become preg-
nant after CC stimulation at our department between
January 2003 and December 2008, 51 were lost to follow-
up (40.8%). Of the remaining 74 patients, 40 age-matched
PCOS women were assigned to the CC group (Group 2).
A total of 109 PCOS women had become pregnant after
metformin therapy alone at our department between Jan-
uary 2003 and December 2008. In these patients, met-
formin had been used as a first-line monotherapy for
PCOS, since these patients wanted an improvement in
both metabolic and reproductive function and were not
on a fast track toward becoming pregnant. Thirty-two
patients were lost to follow-up (29.4%). Of the remaining
77 patients, 40 age-matched PCOS women were assigned
to the metformin group (Group 3). For details on patient
characteristics, see Table 1.
At our department, infertile women with PCOS
undergo a first-line treatment with metformin alone in
case that there is no urgent need to establish pregnancy,
or combined CC stimulation and metformin treatment.
Based on individual decisions with regard to the patient's
needs, LOD is recommended after a minimum of 3 or a
maximum of 6 cycles of CC stimulation has failed to
induce ovulation. Thus, all of our patients (Groups 1, 2,
and 3) had been treated with metformin for at least two
months, with a minimum dose of 1500 mg/day as a stan-
dard, first-line therapy before the pregnancy was estab-
lished. As soon as the pregnancy was diagnosed, the
metformin therapy was discontinued.
Study design
The primary objective of the study was to assess the
adverse events or effects on pregnancy of LOD and CC
stimulation in patients who received metformin and in
patients who received metformin only therapy. The fol-
lowing parameters were analyzed: the rate of multiple
pregnancies; the rate of early pregnancy losses/miscar-
riages; the development of GDM, pregnancy-induced
hypertension (PIH), and preeclampsia/HELLP-syn-
drome; premature delivery; and birth weight.
GDM was diagnosed using the 75 g, 2 h oral glucose
tolerance test (OGTT), routinely performed in the third
trimester. Patients were diagnosed with GDM if one of
the following parameters reached or exceeded the 97.5
percentile: fasting venous blood glucose concentration
(4.5 mmol/l), at 1 h (9.1 mmol/l) and 2 h (7.9 mmol/l).
The indications for OGTT in the second trimester were
as follows: glucose in any of the monthly urine samples;
GDM in a previous pregnancy; diabetes in the immediate
family; and fetal macrosomy (> 2 standard deviations).
PIH was defined as gestational hypertension (blood pres-
sure >140/90 mmHg without proteinuria at a gestational
age >20 weeks on two or more occasions at least 6 h
apart). Preeclampsia was defined as blood pressure >140/
90 mmHg in combination with proteinuria >0.3 g/24 h
after 20 weeks gestation. The HELLP-syndrome was
defined as hemolysis, elevated liver enzymes (serum LDH
≥ 600 IU/L or total bilirubin ≥ 1.2 mg/dL), and low plate-
let count (≤ 100.000 cells/μL). Premature delivery was
considered as delivery between the 22nd and 37th week
of gestation.
Furthermore, we evaluated the following parameters
from retrospective chart review: age; body mass index
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mone (LH), follicle stimulating hormone (FSH), testoster-
one, androstenedione, and oral glucose tolerance test as
measured at the initial visit before any PCOS-related
medication; diabetes mellitus; and pre-existing essential
arterial hypertension and liver diseases before pregnancy
was established.
Surgical technique of laparoscopic ovarian drilling
LOD was achieved with standard laparoscopy under gen-
eral anesthesia. The procedure was performed after
establishing a CO2 pneumoperitoneum. The laparoscope
was inserted through the umbilicus using a 5 mm trocar.
Under direct supervision, two 5-mm adjuvant trocars
were inserted subsequently.
Thirty-one of the reported patients who underwent
LOD were treated with bilateral LOD using a monopolar
electrocoagulation technique, as previously reported [12].
Nine patients were operated with a monopolar hook elec-
trode (GK 375R, B. Braun Aesculap, Maria Enzersdorf,
Austria) and 5-10 incisions of 2-3 mm length in the ovar-
ian capsule.
The study was performed in accordance with the
"Good Scientific Practice Standards" set forth by the
Medical University of Vienna, which are based on the
ethical standards of the revised Helsinki Declaration of
2008. The study was approved by the Institutional Review
Board of the Medical University of Vienna (IRB number:
1121/2009).
Statistical analysis
Variables are described by frequencies and mean ± stan-
dard deviation (SD). Statistical analysis was performed
using the chi-square test, the likelihood-quotient, univar-
iate variance analysis, and the Kruskal-Wallis test. Differ-
ences were considered statistically significant if p < 0.05.
Statistical analysis was performed using SPSS 15.0.1 for
Windows (SPSS Inc., 1989-2006).
Results
Patient characteristics
Details about patient characteristics are listed in Table 1.
The duration of metformin therapy before pregnancy was
longest in the LOD group, followed by the CC group (p <
0.001). For the LOD patients, the time between the oper-
ation and the last menstrual bleeding before conception
was 6.1 ± 2.9 months. These patients had been stimulated
for a minimum of 3 and a maximum of 6 cycles before the
operation. In patients who became pregnant after CC
stimulation, the mean number of stimulations was 1.6 ±
0.8. Pregnancies were established after a stimulation with
50 mg and 100 mg in 30 and 10 patients, respectively.
None of the hormonal parameters were found to differ
between the three groups. No woman had suffered from
diabetes mellitus or any kind of liver disease pre-existing
before pregnancy was established. The incidences of
essential arterial hypertension were distributed equally (p
> 0.05).













Age (years)* 27.8 ± 4.9 27.5 ± 4.5 27.2 ± 4.6 0.204
Parity 0 38 32 34 0.133
1 2 7 6
2 0 1 0
Infertility Prim.+ 25 23 26 0.781
Sec.# 15 17 14
BMI (kg/m2) 26.9 ± 5.0 28.0 ± 6.0 27.2 ± 5.6 0.656
Luteinizing hormone (IU/l)+ 13.5 ± 4.9 14.0 ± 4.2 12.2 ± 4.3 0.349
Follicle stimulating hormone (IU/l)+ 5.9 ± 1.8 6.1 ± 1.7 5.9 ± 1.9 0.917
Testosterone (ng/ml)+ 0.8 ± 0.4 0.7 ± 0.3 0.8 ± 0.3 0.095
Androstendione (ng/ml)+ 3.7 ± 1.1 3.3 ± 1.1 3.4 ± 1.1 0.143
Pre-existing arterial hypertension (n, %)+ 4 (10.0%) 3 (7.5%) 3 (7.5%) 0.897
Abnormal oral glucose tolerance test (n, %)+ 19 (47.5%) 16 (40.0%) 18 (45.0%) 0.789
Duration of metformin therapy (months) 10.1 ± 2.0 6.9 ± 3.1 3.4 ± 1.0 <0.001‡
*Age at conception; +Prim. = primary; #Sec. = secondary; ‡statistically significant;
+ before initiation of any PCOS-related treatment
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Details on early pregnancy courses and outcomes can be
seen in Table 2. There was no case of ovarian hyperstimu-
lation syndrome. The rate of twin pregnancies was high-
est in the CC group (12.5%), followed by the LOD and the
metformin only groups (7.5% and 2.5%, respectively).
However, the differences were not statistically significant
(p = 0.239). All other patients had singleton pregnancies.
Seventeen women suffered from an early miscarriage. In
two patients, the pregnancy was terminated because of
fetal malformations: one 26-year-old woman from the
LOD group for fetal anencephaly in her 17th gestational
week; and one 26-year-old woman from the CC group for
fetal Down syndrome in her 16th gestational week. One
woman from the LOD group suffered a late pregnancy
loss in her 22nd gestational week.
Table 3 shows details outcomes of the 100 pregnancies
remaining after the 24th gestational week. The highest
rate of preterm deliveries before the completed 37th week
of gestation was found for the CC group (19.4%), followed
by the LOD and metformin only groups (8.8% and 5.7%,
respectively). Again, the differences were not significant
(p = 0.200). One male child was delivered by caesarean
section in the 25th week of gestation due to preterm,
prelabor rupture of membranes and intra-amniotic infec-
tion. The child died at the neonatal intensive care unit a
few days after delivery. No other children suffered from
any morbidities in the postpartum period.
The mode of delivery was a caesarean section in 38.2%
(13/34), 51.6% (16/31), and 34.3% (12/35) for groups 1, 2
and 3, respectively. Birth weight did not differ between
groups 1, 2, and 3 (3243.1 ± 628.9 vs. 3261.3 ± 740.9 vs.
3073.3 ± 631.9, respectively; p = 0.253).
Overall pregnancy complication rate
By analyzing all pregnancy complications together, i.e.,
early miscarriage, fetal malformations, late pregnancy
loss, development of PIH, preecmlampsie/HELLP-syn-
drome, and GDM, as well as preterm delivery, the follow-
ing distribution was found: 70.0% (28/40) for the CC
group; 45.0% (18/40) for the LOD group; and 47.5% (19/
40) for the metformin only group (p = 0.047).
Discussion
In this retrospective study of 120 pregnancies after differ-
ent treatment regimes for infertility in PCOS women, we
found no significant differences in pregnancy outcomes,
except for the overall complication rate. However, there
was some trend toward higher early miscarriage, twin
pregnancy, and preterm delivery rates for pregnancies
after CC stimulation.
With regard to general patient characteristics, such as
age, parity, type of infertility, body mass index, hormonal
parameters and the incidence of pre-existing arterial
hypertension, there were no differences between the
three study groups. However, we observed a significantly
longer intake of metformin in the LOD group, followed
by the CC and metformin only groups. This is due to the
fact that metformin is given as the standard first-line
therapy for many anovulatory, young PCOS patients. In
the event that metformin therapy failed to induce ovula-
tion, women were subsequently treated with CC stimula-
tion for a maximum of six cycles. Only CC-resistant
women underwent LOD. However, metformin therapy
was continued during CC stimulation and before and
after LOD. Thus, LOD patients had the longest met-
formin intake.
To our knowledge, this is the first study to compare
pregnancy outcomes after different treatment regimes,
including LOD for anovulatory PCOS women. To date,
only one trial has focused on pregnancy outcomes after
LOD compared to pregnancies after spontaneous ovula-
tion and conception in healthy women. The authors of
that study reported a significantly higher risk of hyper-
tensive disorders and GDM in the LOD group [11]. In our
patient collective, similar incidences of GDM of about
30% were found for the three study groups. Nonetheless,
the overall GDM rate of 30.7% reflects the increased risk
for GDM in patients with PCOS compared to healthy
women [10]. We observed a trend toward a higher risk of












Twin pregnancies 3/40 (7.5%) 5/40 (12.5%) 1/40 (2.5%) 0.239
Early miscarriage 
(<20th week)
4/40 (10.0%) 8/40 (20.0%) 5/40 (12.5%) 0.410
Pregnancy termination 
for fetal malformations
1/36 (2.8%) 1/32 (3.1%) 0 0.441
Late pregnancy loss 
(20th - 24th week)
1/35 (2.9%) 0 0 0.331
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what more profound in the CC group in our study collec-
tive. However, these data failed to reach statistical
significance (p > 0.2). Whether this is caused by possibly
too small sample sizes cannot be concluded from this
data. It is known that, even after LOD, the rates of preg-
nancy-induced hypertensive disorders are increased
when compared to healthy controls [11].
Although statistically not significant, we observed the
highest rate of twin pregnancies after CC stimulation.
This is in accordance with the recent literature reporting
that CC stimulation leads to slightly increased rates of
multiple pregnancies when compared to pregnancies
after spontaneous conception. The multiple pregnancy
rate after CC stimulation in PCOS women has been
reported to be less than 10% [2,10]. The rate of twin preg-
nancies after CC stimulation of 12.5% in our study may be
considered similar.
Rates of early pregnancy loss of up to 40% have been
reported for PCOS women [13]. As mentioned, treatment
with ovulation-inducing medications might be responsi-
ble for this increased risk for early pregnancy loss. This is
in accordance with the observation that CC stimulation
leads to a significantly higher incidence of miscarriage
compared to spontaneous pregnancies in subfertile
women [14]. Similarly, we found the highest rate of early
miscarriage in the CC group in our study (20%), whereas
rates of about 10% were observed in the LOD and met-
formin only groups.
The rate of preterm deliveries before the 37th completed
week of gestation was highest for pregnancies after CC
stimulation (about 20%). Again, these differences were
not significant, perhaps due to the small sample size.
There were no differences in birth weight and neonatal
morbidity or mortality.
We analyzed the overall risk for any kind of pregnancy
complication, and found a significantly higher risk in the
CC group (70%) than in the other groups (about 45%).
This might be an indication that pregnancy after LOD is
somewhat superior to that after CC stimulation in PCOS
patients. However, these data have no validity with regard
to patients who have undergone LOD, but who are still in
need of CC stimulation subsequently in order to become
pregnant. In further studies, we will focuse on this group
of patients.
The additive effect of combined metformin and CC or
metformin and LOD may be a confounding factor. We
consider this a study weakness.
Conclusions
CC, but not LOD for CC resistance, somehow increases
the complication rate in pregnant patients who received
metformin. However, since our study does not demon-
strate a significant benefit of LOD treatment for CC resis-
tance compared to CC stimulation concerning the major
outcome parameters except for the overall complication
rate, LOD cannot be recommended as a first-line therapy
for anovulatory PCOS women under metformin treat-
ment. One has to consider that LOD might lead to a
decrease in the ovarian reserve due to a surgical destruc-
tion of the ovarian capsule and/or to adhesion formation,
both possibly resulting in impairment of fertility. Thus,
LOD must remain a second- or third-line treatment
option [15-18]. Currently, not only ovulation and preg-
nancy rates but also pregnancy outcome, live birth rate,
and baby take-home rate are considered the ultimate clin-
ical endpoints for studies on infertility treatment. Thus,
larger, prospective, randomized trials are necessary in
order to compare pregnancy outcomes after different
treatment regimes for anovulatory infertile PCOS women
and to finally evaluate the value of LOD.
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PIH* 1 (2.9%) 4 (12.5%) 4 (11.4%) 0.262
Preeclampsia/HELLP 
syndrome
4 (11.8%) 4 (12.5%) 1 (2.9%) 0.238
GDM+ 10 (29.4%) 10 (31.3%) 11 (31.4%) 0.980
IGDM# 5 (14.7%) 5 (15.6%) 5 (14.3%) 0.988
Preterm delivery <37th 
gestational week
3 (8.8%) 6 (19.4%) 2 (5.7%) 0.200
*PIH = pregnancy induced hypertension; +GDM = gestational diabetes mellitus; #IGDM = insulin-dependent gestational diabetes mellitus; 
‡statistically significant
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